Olga Borges

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3456188/publications.pdf

Version: 2024-02-01

52 papers	1,936 citations	218381 26 h-index	253896 43 g-index
52 all docs	52 docs citations	52 times ranked	2501 citing authors

#	Article	IF	Citations
1	Preparation of coated nanoparticles for a new mucosal vaccine delivery system. International Journal of Pharmaceutics, 2005, 299, 155-166.	2.6	207
2	Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. Journal of Controlled Release, 2006, 114, 348-358.	4.8	164
3	Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 405-416.	2.0	149
4	Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. European Journal of Pharmaceutical Sciences, 2007, 32, 278-290.	1.9	109
5	Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. International Immunopharmacology, 2008, 8, 1773-1780.	1.7	97
6	Mucosal Vaccines: Recent Progress in Understanding the Natural Barriers. Pharmaceutical Research, 2010, 27, 211-223.	1.7	70
7	Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice. Molecular Pharmaceutics, 2016, 13, 472-482.	2.3	69
8	Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 149-164.	2.0	66
9	Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety. International Journal of Pharmaceutics, 2020, 589, 119776.	2.6	64
10	Hazard Assessment of Polymeric Nanobiomaterials for Drug Delivery: What Can We Learn From Literature So Far. Frontiers in Bioengineering and Biotechnology, 2019, 7, 261.	2.0	62
11	Chitosan Nanoparticles: Shedding Light on Immunotoxicity and Hemocompatibility. Frontiers in Bioengineering and Biotechnology, 2020, 8, 100.	2.0	57
12	Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. International Journal of Pharmaceutics, 2007, 337, 254-264.	2.6	44
13	A Methodological Safe-by-Design Approach for the Development of Nanomedicines. Frontiers in Bioengineering and Biotechnology, 2020, 8, 258.	2.0	44
14	Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-Îµ-caprolactone based nanoparticles. International Journal of Pharmaceutics, 2016, 504, 59-69.	2.6	41
15	A New Strategy Based on Smrho Protein Loaded Chitosan Nanoparticles as a Candidate Oral Vaccine against Schistosomiasis. PLoS Neglected Tropical Diseases, 2012, 6, e1894.	1.3	40
16	Exosomes as adjuvants for the recombinant hepatitis B antigen: First report. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 1-11.	2.0	39
17	Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming. International Journal of Pharmaceutics, 2018, 535, 261-271.	2.6	37
18	Poly(D,L-Lactic Acid) Nanoparticle Size Reduction Increases Its Immunotoxicity. Frontiers in Bioengineering and Biotechnology, 2019, 7, 137.	2.0	35

#	Article	IF	Citations
19	Synthesis and controlled curcumin supramolecular complex release from pH-sensitive modified gum-arabic-based hydrogels. RSC Advances, 2015, 5, 94519-94533.	1.7	33
20	Permeation of sodium dodecyl sulfate through polyaniline-modified cellulose acetate membranes. Polymer, 2005, 46, 5918-5928.	1.8	31
21	Oral Vaccination Based on DNA-Chitosan Nanoparticles againstSchistosoma mansoniInfection. Scientific World Journal, The, 2012, 2012, 1-11.	0.8	31
22	How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept. Frontiers in Bioengineering and Biotechnology, 2020, 8, 165.	2.0	31
23	Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles. International Journal of Pharmaceutics, 2018, 552, 7-15.	2.6	29
24	Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. Pharmaceutics, 2019, 11, 72.	2.0	29
25	Poly-Ïµ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen. Nanomedicine, 2017, 12, 2335-2348.	1.7	29
26	Adjuvant Activity of Poly-Îµ-caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN-Î³ and IL-17 Production. Molecular Pharmaceutics, 2018, 15, 72-82.	2.3	28
27	Glucan Particles Are a Powerful Adjuvant for the HBsAg, Favoring Antiviral Immunity. Molecular Pharmaceutics, 2019, 16, 1971-1981.	2.3	25
28	Chitosan:Î²-glucan particles as a new adjuvant for the hepatitis B antigen. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 33-43.	2.0	23
29	Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. Vaccine, 2015, 33, 3609-3613.	1.7	22
30	Progress Towards a Needle-Free Hepatitis B Vaccine. Pharmaceutical Research, 2011, 28, 986-1012.	1.7	19
31	The effect of methacrylation on the behavior of Gum Arabic as pH-responsive matrix for colon-specific drug delivery. European Polymer Journal, 2016, 78, 326-339.	2.6	19
32	Association of chitosan and aluminium as a new adjuvant strategy for improved vaccination. International Journal of Pharmaceutics, 2017, 527, 103-114.	2.6	18
33	Easy and effective method to generate endotoxin-free chitosan particles for immunotoxicology and immunopharmacology studies. Journal of Pharmacy and Pharmacology, 2019, 71, 920-928.	1.2	18
34	Polymeric nanoengineered HBsAg DNA vaccine designed in combination with Î²â€˜glucan. International Journal of Biological Macromolecules, 2019, 122, 930-939.	3.6	17
35	Optimization of Chitosan-Î±-casein Nanoparticles for Improved Gene Delivery: Characterization, Stability, and Transfection Efficiency. AAPS PharmSciTech, 2019, 20, 132.	1.5	15
36	In vitro anti-Leishmania activity of T6 synthetic compound encapsulated in yeast-derived Î²-(1,3)-d-glucan particles. International Journal of Biological Macromolecules, 2018, 119, 1264-1275.	3.6	14

#	Article	IF	Citations
37	The Inclusion of Chitosan in Poly-Îµ-caprolactone Nanoparticles: Impact on the Delivery System Characteristics and on the Adsorbed Ovalbumin Secondary Structure. AAPS PharmSciTech, 2018, 19, 101-113.	1.5	13
38	Chitosan-Based Nanoparticles as a Hepatitis B Antigen Delivery System. Methods in Enzymology, 2012, 509, 127-142.	0.4	12
39	Biocompatible and high-magnetically responsive iron oxide nanoparticles for protein loading. Journal of Physics and Chemistry of Solids, 2019, 134, 273-285.	1.9	12
40	Safe-by-Design of Glucan Nanoparticles: Size Matters When Assessing the Immunotoxicity. Chemical Research in Toxicology, 2020, 33, 915-932.	1.7	12
41	Poly-Îµ-caprolactone/Chitosan and Chitosan Particles: Two Recombinant Antigen Delivery Systems for Intranasal Vaccination. Methods in Molecular Biology, 2016, 1404, 697-713.	0.4	11
42	Nasal Vaccines Against Hepatitis B: An Update. Current Pharmaceutical Biotechnology, 2015, 16, 882-890.	0.9	10
43	Photophysics and drug delivery behavior of methylene blue into Arabic-gum based hydrogel matrices. Materials Today Communications, 2021, 26, 101889.	0.9	8
44	Unravelling the Immunotoxicity of Polycaprolactone Nanoparticlesâ€"Effects of Polymer Molecular Weight, Hydrolysis, and Blends. Chemical Research in Toxicology, 2020, 33, 2819-2833.	1.7	7
45	Interactions between copper(II) dibrominated salen complex and copolymeric micelles of P-123 and F-127. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2017, 532, 583-591.	2.3	6
46	Early Interaction of Alternaria infectoria Conidia with Macrophages. Mycopathologia, 2019, 184, 383-392.	1.3	6
47	Recent Developments in the Nasal Immunization against Anthrax. World Journal of Vaccines, 2011, 01, 79-91.	0.8	6
48	Validation of a New 96-Well Plate Spectrophotometric Method for the Quantification of Compound 48/80 Associated with Particles. AAPS PharmSciTech, 2013, 14, 649-655.	1.5	5
49	Oral treatment with T6-loaded yeast cell wall particles reduces the parasitemia in murine visceral leishmaniasis model. Scientific Reports, 2019, 9, 20080.	1.6	3
50	Hepatitis B needle-free vaccines: a step closer. Clinical Investigation, 2011, 1, 767-770.	0.0	0
51	Mucosal Vaccination: Opportunities and Challenges. , 2013, , 65-80.		0
52	Guidelines as a starting point to address the needs of small and medium enterprises regarding the Safe-by-Design of polymeric nanobiomaterials for drug delivery. , 2020, , 259-271.		0